Design of early validation trials of biomarkers

Daniel Normolle, Mack T. Ruffin IV, Dean Brenner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The design of early-phase studies of putative screening markers in clinical populations is discussed. Biological, epidemiological, statistical and computational issues all affect the design of early-phase studies of these markers, but there are frequently little or no data in hand to facilitate the design. Early-phase studies must be designed as part of a development program, considering the final use of the marker, directly informing the decision to made at the study's conclusion. Therefore, they should test for sensitivity and specificity that would be minimally acceptable to proceed to the next stage of development. Designing such trials requires explicit assumptions about prevalence and false positive and negative costs in the ultimate target population. Early discussion of these issues strengthens the development process, since enthusiasm for developing technologies is balanced by rea lism about the requirements of a valid population screen. Receiver operating characteristic (ROC) curves, which are useful descriptive tools, may be misleading when evaluating tests in low-prevalence populations, because they emphasize the relationship between specificity and sensitivity in the range of specificity likely to be too low to be useful in mass screening applications.

Original languageEnglish (US)
Pages (from-to)25-31
Number of pages7
JournalCancer Informatics
Volume1
Issue number1
StatePublished - Dec 1 2005

Fingerprint

Biomarkers
Population
Sensitivity and Specificity
Mass Screening
Health Services Needs and Demand
ROC Curve
Hand
Technology
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Normolle, Daniel ; Ruffin IV, Mack T. ; Brenner, Dean. / Design of early validation trials of biomarkers. In: Cancer Informatics. 2005 ; Vol. 1, No. 1. pp. 25-31.
@article{091b72a92e4b4786b63392297917fffe,
title = "Design of early validation trials of biomarkers",
abstract = "The design of early-phase studies of putative screening markers in clinical populations is discussed. Biological, epidemiological, statistical and computational issues all affect the design of early-phase studies of these markers, but there are frequently little or no data in hand to facilitate the design. Early-phase studies must be designed as part of a development program, considering the final use of the marker, directly informing the decision to made at the study's conclusion. Therefore, they should test for sensitivity and specificity that would be minimally acceptable to proceed to the next stage of development. Designing such trials requires explicit assumptions about prevalence and false positive and negative costs in the ultimate target population. Early discussion of these issues strengthens the development process, since enthusiasm for developing technologies is balanced by rea lism about the requirements of a valid population screen. Receiver operating characteristic (ROC) curves, which are useful descriptive tools, may be misleading when evaluating tests in low-prevalence populations, because they emphasize the relationship between specificity and sensitivity in the range of specificity likely to be too low to be useful in mass screening applications.",
author = "Daniel Normolle and {Ruffin IV}, {Mack T.} and Dean Brenner",
year = "2005",
month = "12",
day = "1",
language = "English (US)",
volume = "1",
pages = "25--31",
journal = "Cancer Informatics",
issn = "1176-9351",
publisher = "Libertas Academica Ltd.",
number = "1",

}

Normolle, D, Ruffin IV, MT & Brenner, D 2005, 'Design of early validation trials of biomarkers', Cancer Informatics, vol. 1, no. 1, pp. 25-31.

Design of early validation trials of biomarkers. / Normolle, Daniel; Ruffin IV, Mack T.; Brenner, Dean.

In: Cancer Informatics, Vol. 1, No. 1, 01.12.2005, p. 25-31.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Design of early validation trials of biomarkers

AU - Normolle, Daniel

AU - Ruffin IV, Mack T.

AU - Brenner, Dean

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The design of early-phase studies of putative screening markers in clinical populations is discussed. Biological, epidemiological, statistical and computational issues all affect the design of early-phase studies of these markers, but there are frequently little or no data in hand to facilitate the design. Early-phase studies must be designed as part of a development program, considering the final use of the marker, directly informing the decision to made at the study's conclusion. Therefore, they should test for sensitivity and specificity that would be minimally acceptable to proceed to the next stage of development. Designing such trials requires explicit assumptions about prevalence and false positive and negative costs in the ultimate target population. Early discussion of these issues strengthens the development process, since enthusiasm for developing technologies is balanced by rea lism about the requirements of a valid population screen. Receiver operating characteristic (ROC) curves, which are useful descriptive tools, may be misleading when evaluating tests in low-prevalence populations, because they emphasize the relationship between specificity and sensitivity in the range of specificity likely to be too low to be useful in mass screening applications.

AB - The design of early-phase studies of putative screening markers in clinical populations is discussed. Biological, epidemiological, statistical and computational issues all affect the design of early-phase studies of these markers, but there are frequently little or no data in hand to facilitate the design. Early-phase studies must be designed as part of a development program, considering the final use of the marker, directly informing the decision to made at the study's conclusion. Therefore, they should test for sensitivity and specificity that would be minimally acceptable to proceed to the next stage of development. Designing such trials requires explicit assumptions about prevalence and false positive and negative costs in the ultimate target population. Early discussion of these issues strengthens the development process, since enthusiasm for developing technologies is balanced by rea lism about the requirements of a valid population screen. Receiver operating characteristic (ROC) curves, which are useful descriptive tools, may be misleading when evaluating tests in low-prevalence populations, because they emphasize the relationship between specificity and sensitivity in the range of specificity likely to be too low to be useful in mass screening applications.

UR - http://www.scopus.com/inward/record.url?scp=34047144922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047144922&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34047144922

VL - 1

SP - 25

EP - 31

JO - Cancer Informatics

JF - Cancer Informatics

SN - 1176-9351

IS - 1

ER -